Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey… - Nature medicine, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …
Non-viral precision T cell receptor replacement for personalized cell therapy
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells,–.
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …
COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
Kidney involvement in patients with coronavirus disease 2019 (COVID-19) is common, and
can range from the presence of proteinuria and haematuria to acute kidney injury (AKI) …
can range from the presence of proteinuria and haematuria to acute kidney injury (AKI) …
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related
adverse event and remains poorly understood. In this multicenter analysis, we studied …
adverse event and remains poorly understood. In this multicenter analysis, we studied …
Cytokine storm
Cytokine Storm Cytokine storm, a life-threatening disorder involving cytokine elevations and
immune-cell hyperactivation, has various causes and is characterized by constitutional …
immune-cell hyperactivation, has various causes and is characterized by constitutional …
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less …
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less …
CRISPR–Cas12-based detection of SARS-CoV-2
JP Broughton, X Deng, G Yu, CL Fasching… - Nature …, 2020 - nature.com
An outbreak of betacoronavirus severe acute respiratory syndrome (SARS)-CoV-2 began in
Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 …
Wuhan, China in December 2019. COVID-19, the disease associated with SARS-CoV-2 …
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
S Cordoba, S Onuoha, S Thomas, DS Pignataro… - Nature medicine, 2021 - nature.com
Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable
activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure …
activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure …